Abstract:Altered energy metabolism is a biochemical fingerprint of cancer cells that represents one of the “hallmarks of cancer”. This metabolic phenotype is characterized by preferential dependence on glycolysis (the process of conversion of glucose into pyruvate followed by lactate production) for energy production in an oxygen-independent manner. Although glycolysis is less efficient than oxidative phosphorylation in the net yield of adenosine triphosphate (ATP), cancer cells adapt to this mathematical disadvantage by increased glucose up-take, which in turn facilitates a higher rate of glycolysis. Apart from providing cellular energy, the metabolic intermediates of glycolysis also play a pivotal role in macromolecular biosynthesis, thus conferring selective advantage to cancer cells under diminished nutrient supply. Accumulating data also indicate that intracellular ATP is a critical determinant of chemoresistance. Under hypoxic conditions where glycolysis remains the predominant energy producing pathway sensitizing cancer cells would require intracellular depletion of ATP by inhibition of glycolysis. Together, the oncogenic regulation of glycolysis and multifaceted roles of glycolytic components underscore the biological significance of tumor glycolysis. Thus targeting glycolysis remains attractive for therapeutic intervention. Several preclinical investigations have indeed demonstrated the effectiveness of this therapeutic approach thereby supporting its scientific rationale. Recent reviews have provided a wealth of information on the biochemical targets of glycolysis and their inhibitors. The objective of this review is to present the most recent research on the cancer-specific role of glycolytic enzymes including their non-glycolytic functions in order to explore the potential for therapeutic opportunities. Further, we discuss the translational potential of emerging drug candidates in light of technical advances in treatment modalities such as image-guided targeted delivery of cancer therapeutics.

Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach

Advancement in Transporter-Oriented Nanoplatforms for Cancer Therapy

Glucose transporters in cancer – from tumor cells to the tumor microenvironment

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Metabolic Targeting of Cancers: from Molecular Mechanisms to Therapeutic Strategies

Development of Glucose Transporter (GLUT) Inhibitors

Sodium-glucose cotransporters: new targets of cancer therapy?

The emerging role of targeting cancer metabolism for cancer therapy

Tumor glycolysis as a target for cancer therapy: progress and prospects

Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics

SGLT2 Inhibitors as Potential Anticancer Agents

GLUT1: a Promising Drug Target for Cancer Treatment

Structural Aspects of the Glucose and Monocarboxylate Transporters Involved in the Warburg Effect

Targeting cellular metabolism to improve cancer therapeutics

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

Regulating Glucose Metabolism Using Nanomedicines for Cancer Therapy.

Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review

The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism

Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression

Metabolic Alterations in Cancer Cells and Therapeutic Implications.

Glucose Metabolism and Glucose Transporters in Breast Cancer